Hutchmed (China) Newsroom

Orient: Initiates a "Buy" rating for Hutchmed (China) (00013) with a Target Price of 33.24 HKD.

Zhitong FinanceDec 27 09:19

【Brokerage Focus】Orient gives Hutchmed (China) (00013) an initial "Buy" rating as innovative products yield results.

Jinwu Financial NewsDec 27 09:10

Hehuang Pharmaceutical (00013.HK): PIPELINE has blossomed and the results of going out to sea are being realized

OrientDec 27 07:32

Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target

MT NewswiresDec 19 20:40

GF Securities: Maintaining the reasonable value of Hewang Pharmaceutical's (00013) “buy” rating of HK$41.35

Zhitong FinanceDec 12 09:32

Hehuang Pharmaceutical (00013.HK): New Indications for Fruquintinib Approved to Verify Combined Therapy Potential

GF SECDec 10 00:00

Hehuang Pharmaceutical (00013.HK): Progress has been made in clinical development and commercialization

guosenDec 3 07:42

Hehuang Pharmaceutical (00013.HK): Syvortinib successfully renewed health insurance negotiations, US production is about to be reported

soochowDec 1 07:12

CICC: Maintains hutchmed (china) 'outperform' rating with a target price of HK$38.25.

Zhitong FinanceNov 8 09:33

Hehuang Pharmaceutical (00013.HK): FRUZAQLA met expectations for the third quarter ESLIM-01 data update

china international capital corporationNov 8 07:47

Brokerage Focus: Northeast Securities maintains a "buy" rating on Hutchmed (China) (00013), pointing out its wide product market space and the potential for continuous overseas expansion.

King Gold Financial NewsOct 17 15:20

Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17 09:53

Hehuang Pharmaceutical (00013) Company News Review: Phase II clinical trials of sevotinib combination therapy showed improvement in ORR

Northeast SecuritiesOct 16 18:41

swhy: First initiated a "buy" rating on hutchmed (china) (00013) with a target price of 35.4 Hong Kong dollars

Zhitong FinanceSep 25 17:26

Hehuang Pharmaceutical (00013.HK): Focus on the small molecule field of fruquintinib to achieve overseas commercialization

swhy researchSep 25 12:16

Citi: Maintains 'buy' rating on hutchmed (china) (00013), target price reduced to 38.9 Hong Kong dollars

Zhitong FinanceSep 2 13:30

Huhuang Pharmaceutical (0013.HK): Overseas sales of furoquintinib exceeded expectations, and the innovation pipeline accelerated

Aug 9 18:36

Hutchison Whampoa (00013.HK): Continued progress in overseas sales

Aug 7 07:21

US stocks change: Hutchmed (China) rose more than 7% in pre-market trading. CMB International raised its target price for H shares and maintained a 'buy' rating.

Gelonghui FinanceAug 6 16:16

Robust Sales and Expansion Potential Underpin Buy Rating for HUTCHMED

TipRanksAug 5 18:27